En rouge : les articles phares pilotés par LNOx 2022 Gyan E, Arnaud Pigneux4, Hunault M, Peterlin P, Carré M, Bay JO, Bonmati C, Gallego‐Hernanz MP, Lioure B, Bertrand P, Vallet N, Ternant D, Darrouzain F, Picou F, Béné MC, Récher C, Hérault O. (2022) Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high‐risk AML. Sci Rep, 12:9748 (IF2020= 4,380) Potier-Cartereau M, Gautier M, Ravalet N, Ducrocq E, Hamard S, LeGuennec JY, Vandier C, Herault O. (2022) The sodium-calcium exchanger control the membrane potential of AFT024, a mesenchymal stem cell hematopoietic niche forming line. Biolectricity, 4:103-107 Dakik H, El Dor M, Bourgeais J, Kouzi F, Herault O, Gouilleux F, Zibara K, Mazurier F. (2022) Diphenyleneiodonium triggers cell death of acute myeloid leukaemia cells by blocking the mitochondrial respiratory chain and synergizes with Cytarabine. Cancers (Basel), 14:2485 (IF2020= 6,639) Roux B, Picou F, Debeissat C, Koubi M, Gallay N, Hirsch P, Ravalet N, Bene MC, Maigre M, Hunault M, Mosser J, Etcheverry A, Gyan E, Delhommeau F, Domenech J, Herault O. (2022) Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia. Cancer Gene Ther, 22fev2022, doi.org/10.1038/s41417-022-00441-w (IF2020= 5,987) Eveillard M, Bene MC, Herault O. (2022) Letter to the editor with regard to the article entitled “Automated leukocyte parameters are useful in the assessment of myelodysplastic syndromes.” Cytometry B Clin Cytom, 102:76 (IF2020= 3,058) Le Nail LR, Crenn V, Rosset P, Ropars M. (2022) Management of adipose tumors in the limbs. Orthop Traumatol Surg Res, 108(1S):103162. (IF2020= 2,256) Dakik H, El Dor M, Bourgeais J, Kouzi F, Herault O, Gouilleux F, Zibara K, Mazurier F. (2022) Diphenyleneiodonium triggers cell death of acute myeloid leukemia cells by blocking the mitochondrial respiratory chain, and synergizes with cytarabine. Cancers (Basel), 14:2485 Platel V, Lechevalier D, Bourreau C, Šoborová I, Jeannière C, Martin L, Hérault O, Corre I, Clere N. (2022) NOX1 and NOX2: two enzymes that promote endothelial-to-mesenchymal transition induced by melanoma conditioned media. Pharmacol Res, 24:106097 (IF2020= 7,568) Sureau L, Buors C, ianotto JC, Boyer F, Tanguy-Schmidt A, Roy L, Cayssials E, Chomel JC, Chauveau A, Orvain C, Mansier O, Ranta D, Robles M, Gyan E, Herault O, Nimubona S, Marchand T, Lippert E, Riou J, Ugo V, Luque Paz D. (2022) JAK2 V617F polycythemia vera and essential thrombocythemia: Dynamic Clinical features associated with long-term outcomes. Blood Cancer J, 12:56 (IF2020= 11,037) Lanznaster D, Bruno C, Bourgeais J, Emond P, Zemmoura I, Lefèvre A, Reynier P, Eymieux S, Blanchard E, Vourc'h P, Andres CR, Bakkouche SE, Herault O, Favard L, Corcia P, Blasco H. (2022) Metabolic profile and pathological alterations in the muscle of patients with early-stage amyotrophic lateral sclerosis. Biomedicines, 10:1307 (IF2020= 4,757) Guillon A, Bréa D, Cezard A, Baranek T, Bourgeais J, Picou F, Vasseur V, Meyer L, Carballido JM, Nadal Desbarats L, Auvet A, Dingli F, Turtoi A, Le Gouellec A, Fauvelle F, Donchet A, Crépin T, Hiemstra PS, Paget C, Loew D, Herault O, Naffakh N, Le Goffic R, Si-Tahar M. (2022) Host succinate inhibits influenza virus infection through succinylation and nuclear retention of the viral nucleoprotein. EMBO J 2022 May 4:e108306. doi: 10.15252/embj.2021108306 (IF2020= 11,598) Gueginou M, Ibrahim S, Bourgeais J, Robert A, Pathak T, Zhang X, Dupuy J, Ternant D, Monbet V, Guibon R, Flores-Romero H, Lefèvre A, Lerondel S, Le Pape A, Dumas, JF, Frank PG, Girault A, Chautard R, Guéraud F, Garcia-Saez AJ, Ouaissi M, Emond P, Sire O, Herault O, Fromont-Hankard G, Vandier C, Tougeron D, Trebak M, Raoul W, Lecomte T. (2022) Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer. Cell Mol Life Sci, 79:284 (IF2020= 9,261) Delaye JB, Alarcan H, Vallet N, Veyrat-Durebex C, Bernard L, Hérault O, Ropert M, Marlet J, Gyan E, Andres C, Blasco H, Piver E. (2022) Specific changes of erythroid regulators and hepcidin in patients infected by SARS-COV-2. J Investig Med, jim-2021-002270. (IF2020= 2,895) Lanznaster D, Bruno C, Bourgeais J, Emond P, Zemmoura I, Lefèvre A, Reynier P, Eymieux S, Blanchard E, Vourc'h P, Andres CR, Bakkouche SE, Herault O, Favard L, Corcia P, Blasco H. (2022) Metabolic profile and pathological alterations in the muscle of patients with early-stage amyotrophic lateral sclerosis. Biomedicines, 10:1307 (IF2021= 6,081) Sekeres MA, Schuster M, Joris M, Krauter J, Maertens J, Breems D, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang ES, Ching K, O'Brien T, Gallo Stampino C, Ma WW, Kudla A, Chan G, Zeidan AM. (2022) A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes. Ann Hematol. 2022 Apr 30. doi: 10.1007/s00277-022-04853-4 Drevin G, Briet M, Bazzoli C, Gyan E, Schmidt A, Dombret H, Orvain C, Giltat A, Recher C, Ifrah N, Guardiola P, Hunault-Berger M, Abbara C. (2022) Daunorubicin and its active metabolite pharmacokinetic profiles in acute myeloid leukaemia patients: A pharmacokinetic ancillary study of the BIG-1 Trial. Pharmaceutics. 14:792. doi: 10.3390/pharmaceutics14040792. Slomka F, Druon J, Rosset P, Le Nail LR. (2022) Fully hydroxyapatite-coated distal locking cementless femoral modular implant for revision total hip arthroplasty: A retrospective study of 94 Renaissance™ stems at a minimum 10 years' follow-up. Orthop Traumatol Surg Res. 2022 Feb 3:103233. (IF2020= 2,256) Halimi JM, Thoreau B, von Tokarski F, Bauvois A, Gueguen J, Goin N, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Lemaignen A, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Frémeaux-Bacchi V, Vigneau C, Bayer G, Fakhouri F. (2022) What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective study. BMC Nephrol, 23:39 (IF2020= 2,388) Salaün H, Le Nail LR, Simon C, Narciso B, De Pinieux G, Vegas H, Vinceneux A. (2022) Unexpected severe hepatic and skin toxicities during high dose methotrexate course for osteosarcoma. J Oncol Pharm Pract. 2022 Feb 9:10781552221076456. 2021 Foucault A, Ravalet N, Besombes J, Picou F, Gallay N, Corset L, Bourgeais J, Hamard S, Domenech J, Loyer P, Vallet N, Lejeune J, Gyan E, Béné MC, Vallette F, Olivier C, Herault O. Low-dose pesticides alter primary human bone marrow mesenchymal stem/stromal cells through ALDH2 inhibition. Cancers, 13:5699 (IF2020= 6,639) Mancini SJC, Balabanian K, Corre I, GavardJ, Le Bousse-Kerdilès MC, Lazennec G, Louache F, Maguer-Satta V, Mazure NM, Mechta-Grigoriou F, Peyron JF, Trichet V, Herault O. (2021) Deciphering tumor niches: lessons from solid and hematological malignancies. Front Immunol, 12:766275 (IF2020= 7,561) Bourgeais J, Herault O. (2021) In Vitro Analysis of Energy Metabolism in Bone-Marrow Mesenchymal Stromal Cells. In: Espéli M., Balabanian K. (eds) Bone Marrow Environment. Meth Mol Biol, 23084 (15):3550-3557. (IF2020= 38,315) Dakik H, El Dor M, Leclerc J, Kouzi F, Nehme A, Deynoux M, Debeissat C, Khamis G, Ducrocq E, Ibrik A, Stasia MJ, Raad H, Reza Rezvani H, Gouilleux F, Zibara K, Herault O, Mazurier F. (2021) Characterization of NADPH oxidase expression and activity in acute myeloid leukemia cell lines: a correlation with the differentiation status. Antioxidants, 10:498 (IF2020= 6,312) Foucault A,* Vallet N,* Ravalet N, Picou F, Bene MC, Gyan E, Herault O. (2021) Occupational pesticide exposure increases risk of acute myeloid leukemia: a meta-analysis of case-control studies including 3,955 cases and 9,948 controls. Sci Rep, 11:2007 *equal contributors (IF2020= 4,379) Ravalet N,* Foucault A,* Picou F,* Gombert M, Renoult E, Lejeune J, Vallet N, Lachot S, Rault E, Gyan E, Bene MC, Herault O. (2021) Automated early detection of myelodysplastic syndrome within the general population using the research parameters of Beckman-Coulter DxH 800 hematology analyzer. Cancers (Basel), 13:389 *equal contributors (IF2020= 6,639) Lejeune J, Fouquereau E, Chênevert D, Coillot H, Chevalier S, Gillet N, Michon JM, Gandemer V, Colombat P. (2021) The participatory approach: a specific French organizational model at the department level to serve the quality of work life of healthcare providers and the quality of care in pediatric oncology. Cancer Manag Res, 13:2763-2771 (IF2020= 2,886) Bou Tayeh B, Salem N, Laletin V, Just-Landi S, Joanna F, Leblanc R, Balzano M, Kerdiles YM, Bidaut G, Herault O, Olive D, Aurrand-Lions M, Walzer T, Nunes JA, Fauriat C. (2021) Chronic IL-15 stimulation and impaired mTOR signaling and metabolism in natural killer cells during acute myeloid leukemia. Front Immunol, 12:730970 (IF2020= 7,561) Vallet N, Delaye JB, Ropert M, Foucault A, Ravalet N, Deriaz S, Chalopin T, Blasco H, Maillot F, Hérault O, Gyan E. (2021) Megaloblastic anemia-related iron overload and erythroid regulators: a case report. J Med Case Rep, 15:463 Thoreau B, von Tokarski F, Bauvois A, Bayer G, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Frémeaux-Bacchi V, Vigneau C, Fakhouri F, Halimi JM. (2021) Infection in patients with suspected thrombotic microangiopathy based on clinical presentation. Clin J Am Soc Nephrol, 16:1355-1364 Haméon C, Rousselot C, Arbion F, Cibron J, Cottier JP, Destrieux C, Hérault O, Gyan E. (2021) Cerebral localization of chronic myelomonocytic leukemia: a case report. J Med Case Rep, 15:368 Chalopin T, Vallet N, Theisen O, Ochmann M, Tiab M, Godmer P, Barin C, Hérault O, Gyan E, Le Gouill S, Avet-Loiseau H, Benboubker L, Moreau P, Touzeau C. (2021) No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. Br J Haematol, 2021 Apr 29. doi: 10.1111/bjh.17488 Chalopin T, Vallet N, Morel M, Maguet R, d'Alteroche L, de Pinieux G, Hérault O, Gyan E, Sutton L, Villate A. (2021) Eosinophilic fasciitis (Shulman syndrome), a rare entity and diagnostic challenge, as a manifestation of severe chronic graft-versus-host disease: a case report. J Med Case Rep 15:135 Fahy L, Calvo J, Chabi S, Renou L, Le Maout C, Poglio S, Leblanc T, Petit A, Baruchel A, Ballerini P, Naguibneva I, Haddad R, Arcangeli ML, Mazurier F, Pflumio F, Uzan B. (2021) Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop. Blood Adv 5:513-526 Stocker M, Le Nail LR, De Belenet H, Wunder JS, Andrulis IL, Gokgoz N, Levy N, Mattei JC, Olschwang S. (2021) Inhibition of P53-mediated cell cycle control as the determinant in dedifferentiated liposarcomas development. Am J Cancer Res, 11:3271-3284 Bensalem A, Cartron G, Specks U, Mulleman D, Gyan E, Cornec D, Desvignes C, Casasnovas O, Lamy T, Leprêtre S, Paintaud G, Ternant D. (2021) The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition. Clin Pharmacokinet. 2021 Nov 13. doi: 10.1007/s40262-021-01081-3 Sellner L, Schetelig J, Koster L, Choi G, Blaise D, Beelen D, Schianca FC, Passweg J, Schanz U, Gyan E, Sora F, Kröger N, Wulf GG, Van Gorkom G, Mayer J, Orvain C, Bourhis JH, Jindra P, Potter V, Zallio F, Vandenberghe E, Robinson S, Hayden PJ, Yakoub-Agha I, Montoto S, Dreger P; European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties. (2021) Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey. Bone Marrow Transplant 2021 Oct 7. doi: 10.1038/s41409-021-01490-9 Marlet J, Gatault P, Maakaroun Z, Longuet H, Stefic K, Handala L, Eymieux S, Gyan E, Dartigeas C, Gaudy-Graffin C. Antibody responses after a third dose of COVID-19 vaccine in kidney transplant recipients and patients treated for chronic lymphocytic leukemia. Vaccines (Basel), 9:1055 Mercier M, Orvain C, Drieu La Rochelle L, Marchand T, Nunes Gomes C, Giltat A, Paillassa J, Clavert A, Farhi J, Rousselet MC, Gyan E, Houot R, Moles-Moreau MP, Hunault-Berger M. (2021) Impact of high-dose methotrexate on the outcome of patients with diffuse large B-cell lymphoma and skeletal involvement. Cancers (Basel), 13:2945 Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster H, Hiddemann W, Marcus RE, Kimby EK, Herold M, Sebban CJ, Gyan E, Foon KA, Nielsen TG, Vitolo U, Salles GA, Shi Q, Flowers CR. (2021) Validation of POD24 as a robust early clinical endpoint of poor survival in FL from 5,225 Patients on 13 clinical trials. Blood, 2021 Oct 6;blood.2020010263. doi: 10.1182/blood.2020010263 Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Le Bras F, Willems E, Tchernonog E, Chalopin T, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquières H, Tournilhac O, Gomesda Silva M, Bouabdallah R, Salles G, Bachy E. (2021) Corrigendum to 'Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers': [Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723]. Ann Oncol, 32:945 Lam M, Touitou V, Choquet S, Cassoux N, Ghesquières H, Kodjikian L, Schmitt A, Gattoussi S, Tabouret É, Sampo M, Blonski M, Angioi-Duprez K, Houot R, Mouriaux F, Gyan E, Le Lez ML, Moles MP, Croisé F, Chauchet A, Schwartz C, Ahle G, Meyer L, Gressin R, Chiquet C, Oberic L, Ollé P, Marolleau JP, Jany B, Tempescul A, Cochener B, Damaj G, Quintyn JC, Moluçon-Chabrot C, Rousseau E, Franciane P, Schneider C, Massé H, Tamburini-Bonnefoy J, Brézin A, Fornecker LM, Ballonzoli L, Le Garff-Tavernier M, Hoang-Xuan K, Bodaghi B, Soussain C, Houillier C. (2021) Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study. Am J Hematol, 96:823-833 Bouvier A, Hamel JF, Delaunay J, Delabesse E, Dumas PY, Ledoux MP, Peterlin P, Luquet I, Roth Guepin G, Bulabois CE, Gallego Hernanz MP, Guillerm G, Guieze R, Hicheri Y, Simand C, Himberlin C, Hunault-Berger M, Bernard M, Jourdan E, Caillot D, Dorvaux V, Tavernier E, Daguindau E, Banos A, Ojeda-Uribe M, Gyan E, Alexis M, Marolleau JP, Turlure P, Bouscary D, Humbrecht C, Zerazhi H, Béné MC, Pigneux A, Carre M, Ifrah N, Blanchet O, Vey N, Récher C, Cornillet-Lefèbvre P; French Innovative Leukemia Organization. (2021) Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial. Eur J Haematol 107:111-121 Comont T, Meunier M, Cherait A, Santana C, Cluzeau T, Slama B, Laribi K, Giraud JT, Dimicoli S, Berceanu A, Le Clech L, Cony-Makhoul P, Gruson B, Torregrosa J, Sanhes L, Jachiet V, Azerad MA, Al Jijakli A, Gyan E, Gaudin C, Broner J, Guerveno C, Guillaume T, Ades PL, Beyne-Rauzy O, Fenaux P; Groupe Francophone des Myélodysplasies (GFM). (2021) Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study. Br J Haematol, 194:336-343 Tessoulin B, Chiron D, Thieblemont C, Oberic L, Bouadballah K, Gyan E, Damaj G, Ribrag V, Gressin R, Feugier P, Casasnovas O, Zerazhi H, Lemonnier F, Maisonneuve H, Joubert C, Van Den Neste E, Lamy T, Tilly H, Moreau A, Hermine O, Le Gouill S. (2021) Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. Bone Marrow Transplant, Mar 3. doi: 10.1038/s41409-020-01198-2 Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler AP, Maloisel F, Rea D, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Jourdan E, Berger M, Fouillard L, Alexis M, Legros L, Rousselot P, Delmer A, Lenain P, Escoffre Barbe M, Gyan E, Bulabois CE, Dubruille V, Joly B, Pollet B, Cony-Makhoul P, Johnson-Ansah H, Mercier M, Caillot D, Charbonnier A, Kiladjian JJ, Chapiro J, Penot A, Dorvaux V, Vaida I, Santagostino A, Roy L, Zerazhi H, Deconinck E, Maisonneuve H, Plantier I, Lebon D, Arkam Y, Cambier N, Ghomari K, Miclea JM, Glaisner S, Cayuela JM, Chomel JC, Muller M, Lhermitte L, Delord M, Preudhomme C, Etienne G, Mahon FX, Nicolini FE; France Intergroupe des Leucémies Myéloïdes Chroniques, Fi-LMC. Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia, Jan 22. doi: 10.1038/s41375-020-01117-w Schmitz N, Truemper LH, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner-Drouet EM, Wilhelm M, Sanhes L, Lamy T, de Leval L, Rosenwald A, Roussel M, Kroschinsky FP, Lindemann WW, Dreger P, Viardot A, Milpied NJ, Gisselbrecht C, Wulf GG, Gyan E, Gaulard P, Bay JO, Glass B, Poeschel V, Damaj G, Sibon D, Delmer AJ, Bilger K, Banos A, Haenel M, Dreyling M, Metzner B, Keller U, Braulke F, Friedrichs B, Nickelsen M, Altmann B, Tournilhac O. (2021) A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood, 137:2646-2656 Laude MC, Lebras L, Sesques P, Ghesquieres H, Favre S, Bouabdallah K, Croizier C, Guieze R, Drieu La Rochelle L, Gyan E, Chin R, Aurran-Schleinitz T, Marouf A, Deau-Fischer B, Coppo P, Malot S, Roussel X, Chauchet A, Schwarz M, Bescond C, Lamy de la Chapelle T, Bussot L, Carras S, Burlet B, Rossi C, Daniel A, Morschhauser F, Subtil F, Michallet AS. (2021) First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study. Am J Hematol, 96:302-311 Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, Godwin JE, Arellano ML, Sweet K, Emadi A, Ravandi F, Erba HP, Byrne M, Michaelis LC, Topp MS, Vey N, Ciceri F, Carrabba MG, Paolini S, Huls G, Jongen-Lavrencic M, Wermke M, Chevallier P, Gyan E, Récher C, Stiff P, Pettit K, Löwenberg B, Church S, Anderson EK, Vadakekolathu J, Santaguida MT, Rettig MP, Muth J, Curtis T, Fehr E, Guo K, Zhao J, Bakkacha O, Jacobs K, Tran K, Kaminker P, Kostova M, Bonvini E, Walter RB, Davidson-Moncada JK, Rutella S, DiPersio JF. (2021) Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. Blood, 137:751-762 Brulin B, Nolan JC, Marangon T, Kovacevic M, Chatelais M, Meheust P, Abadie J, Le Nail LR, Rosset P, Brennan MÁ, Layrolle P. (2021) Evaluation of the chemotherapy drug response using organotypic cultures of osteosarcoma tumours from mice models and canine patients. Cancers (Basel), 13:4890 Burgade R, Bisson-Patoue A, Rosset P, Bourdais-Sallot A, Le Nail LR. (2021) Anatomical basis of gluteus maximus and application as a pedicled cover flap for pelvic tumor resections. Ann Chir Plast Esthet, S0294-1260(21)00076-5. Fayet Y, Tétreau R, Honoré C, Le Nail LR, Dalban C, Gouin F, Causeret S, Piperno-Neumann S, Mathoulin-Pelissier S, Karanian M, Italiano A, Chaigneau L, Gantzer J, Bertucci F, Ropars M, Saada-Bouzid E, Cordoba A, Ruzic JC, Varatharajah S, Ducimetière F, Chabaud S, Dubray-Longeras P, Fiorenza F, De Percin S, Lebbé C, Soibinet P, Michelin P, Rios M, Farsi F, Penel N, Bompas E, Duffaud F, Chevreau C, Le Cesne A, Blay JY, Le Loarer F, Ray-Coquard I. (2021) Determinants of the access to remote specialised services provided by national sarcoma reference centres. BMC Cancer, 21:631 Beaufort Q, Terrier LM, Dubory A, Le Nail LR, Cook AR, Cristini J, Buffenoir K, Pascal-Moussellard H, Carpentier A, Mathon B, Amelot A. (2021) Spine Metastasis in Elderly: Encouraging Results for Better Survival. Spine (Phila Pa 1976), 46:751-759 Amelot A, Terrier LM, Le Nail LR, Cristini J, Cook AR, Buffenoir K, Pascal-Moussellard H, Carpentier A, Dubory A, Mathon B. (2021) Spine metastasis in patients with prostate cancer: Survival prognosis assessment. Prostate, 81:91-101 Fujiwara T, Stevenson J, Parry M, Le Nail LR, Tsuda Y, Grimer R, Jeys L. (2021) Pelvic reconstruction using an ice-cream cone prosthesis: correlation between the inserted length of the coned stem and surgical outcome. Int J Clin Oncol, 26:1139-1146 Fujiwara T, Grimer RJ, Evans S, Medellin Rincon MR, Tsuda Y, Le Nail LR, Abudu S. (2021) Impact of NICE guidelines on the survival of patients with soft-tissue sarcomas. Bone Joint J, 103-B(3):569-577 2020 Vignon C,* Debeissat C,* Bourgeais J, Gallay N, Kouzi F, Anginot A, Picou F, Guardiola P, Ducrocq E, Foucault A, Ravalet R, Le Nail LR, Domenech J, Béné MC,Le Bousse-Kerdilès MC, Gyan E, Herault O. (2020) Involvement of GPx-3 in the reciprocal control of redox metabolism in the leukemic niche. Int J Mol Sci, 21:8584 *equal contributors (IF2020= 5,923) Vignon C,* Lachot S,* Foucault A, Ravalet N, Gyan E, Picou F, Herault B, Le Nail LR, Bene MC, Herault O. (2020) Reactive oxygen species levels differentiate CD34+ human progenitors based on CD38 expression. Cytometry B Clin Cytom, 98:516-521. *equal contributors (IF2020= 3,058) Nehme A, Dakik H, Picou F, Cheok M, Preudhomme C, Dombret H, Lambert J, Gyan E, Pigneux A, Recher C, Béné MC, Gouilleux F, Zibara K, Herault O, Mazurier F. (2020) Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing robust prognostic signature. Blood Adv, 4:5322-5335 (IF2020= 6,686) El Dor M, Dakik H, Polomski M, Haudebourg E, Brachet M, Gouilleux F, Prié G, Zibara K, Mazurier F. (2020) VAS3947 induces UPR-mediated apoptosis through cysteine thiol alkylation in AML cell lines. Int J Mol Sci, 21:5470 (IF2020= 5,923) Hallal R, Nehme R, Brachet-Botineau M, Nehme A, Dakik H, Deynoux M, Dello Sbarba P, Levern Y, Zibara K, Gouilleux F, Mazurier F. (2020) Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells. J Cell Mol Med, 24:10052-10062 (IF2020= 5,310) Guermouche H,* Ravalet N,* Gallay N,* Deswarte C, Foucault A, Beaud J, Rault E, Saindoy E, Lachot S, Martignoles J, Gissot V, Suner L, Gyan E, Delhommeau F,# Herault O,# Hirsch P#. (2020) High prevalence of clonal hematopoiesis in the blood and the bone marrow of healthy volunteers. Blood Adv, 4:3550-3557. *,# equal contributors. (IF2020= 6,686) Kouzi F, Zibara K, Bourgeais J, Picou F, Gallay N, Brosseau J, Dakik H, Roux B, Hamard S, Le Nail LR, Hleihel R, Foucault A, Ravalet N, Rouleux-Bonnin F, Gouilleux F, Mazurier F, Bene MC, Akl H, Gyan E, Domenech J, El-Sabban M, Herault O. (2020) Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells. Oncogene, 39:1198-1212 (IF2020= 9,867) Deynoux M, Sunter N, Ducrocq E, Dakik H, Guibon R, Burlaud-Gaillard J, Brisson L, Rouleux-Bonnin F, Le Nail LR, Hérault O, Domenech J, Roingeard P, Fromont G, Mazurier F. (2020) A comparative study of the capacity of mesenchymal stromal cell lines to form spheroid. PLoS One 15:e0225485. (IF2020= 3,240) Coste E, Rouleux-Bonnin F. (2020) The crucial choice of reference genes: identification of miR-191-5p for normalization of miRNAs expression in bone marrow mesenchymal stromal cell and HS27a/HS5 cell lines. Sci Rep 10:17728. doi: 10.1038/s41598-020-74685-7 (IF2020= 4,379) Brachet-Botineau M, Polomski M, Neubauer HA, Juen L, Hédou D, Viaud-Massuard MC, Prié G, Gouilleux F. (2020) Pharmacological inhibition of oncogenic STAT3 and STAT5 signaling in hematopoietic cancers. Cancers (Basel), 12: pii: E240. Review. (IF2020= 6,639) Meyenberg M, Fabbri L, Dufies M, Lacas-Gervais S, Contenti J, Voyton C, Fazio S, Irondelle M, Mograbi B, Rouleau M, Sadaghianloo N, Rovini A, Brenner C, Craigen W, Bourgeais J, Herault O, Bost F, Mazure NM. (2020) Evidences of a direct relationship between cellular fuel supply and ciliogenesis regulated by hypoxic VDAC1-ΔC. Cancers 2020, 12:3484 doi:10.3390/cancers12113484 Caillot M, Zylbersztejn F, Maitre E, Bourgeais J, Hérault O, Sola B. (2020) ROS overproduction sensitises myeloma cells to bortezomib-induced apoptosis and alleviates tumour microenvironment-mediated cell resistance. Cells, 9:2357 doi:10.3390/cells9112357 Polomski M, Brachet-Botineau M, Juen L, Viaud-Massuard MC, Gouilleux F, Prié G. (2020) Inhibitors targeting STAT5 signaling in myeloid leukemias: new tetrahydroquinoline derivatives with improved antileukemic potential. ChemMedChem 2020 Dec 4. doi: 10.1002/cmdc.202000841 Blasco H, Bessy C, Plantier L, Lefevre A, Piver E, Bernard L, Marlet J, Stefic K, Benz De Bretagne I, Cannet P, Lumbu H, Morel T, Boulard P, Andres CR, Vourch P, Herault O, Guillon A, Emond P. (2020) The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism. Sci Rep, 10:16824. doi.org/10.1038/s41598-020-73966-5 Hergesheimer R, Lanznaster D, Bourgeais J, Hérault O, Vourc'h P, Andres CR, Corcia P, Blasco H. (2020) Conditioned medium from cells overexpressing TDP-43 alters the metabolome of recipient cells. Cells 2020 Sep 29;9(10):E2198. doi: 10.3390/cells9102198. Nehme R, Hallal R, El Dor M, Kobeissy F, Gouilleux F, Mazurier F, Zibara K. (2020) Repurposing of Acriflavine to target Chronic Myeloid Leukemia treatment. Curr Med Chem 2020 Sep 8. doi: 10.2174/0929867327666200908114411 Caillot M, Bourgeais J, Dakik H, Coste E, Hamadouche N, Mazure N, Lelièvre E, Coqueret O, Herault O, Mazurier F, Sola B. (2020) Cyclin D1 targets hexokinase 2 for controlling aerobic glycolysis in myeloma cells. Oncogenesis, 9:68 Chalopin T, Vallet N, Benboubker L, Ochmann M, Gyan E, Chaumier F. (2020) Retrospective review of end-of-life care in the last month of life in older patients with multiple myeloma: what collaboration between haematologists and palliative care teams? BMJ Support Palliat Care. 2020 Sep 4:bmjspcare-2020-002293. doi: 10.1136/bmjspcare-2020-002293 Hadzijusufovic E, Keller A, Berger D, Greiner G, Wingelhofer B, Witzeneder N, Ivanov D, Pecnard E, Nivarthi H, Schur FKM, Filik Y, Kornauth C, Neubauer HA, Müllauer L, Tin G, Park J, de Araujo ED, Gunning PT, Hoermann G, Gouilleux F, Kralovics R, Moriggl P, Valent P. (2020) STAT5 is expressed in CD34 +/CD38 - stem cells and serves as a potential molecular target in Ph-negative myeloproliferative neoplasms. Cancers (Basel), 12:1021 Tessoulin B, Bouabdallah K, Burroni B, Lamy T, Gressin R, Cartron G, Thieblemont C, Sarkozy C, Haioun C, Casasnovas O, Joubert C, Gyan E, Hermine O, Le Gouill S. (2020) Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T 3 phase IB Trial of the LYSA. Ann Hematol, 99:1771-1778 Le Bris Y, Magrangeas F, Moreau A, Chiron D, Guérin-Charbonnel C, Theisen O, Pichon O, Canioni D, Burroni B, Maisonneuve H, Thieblemont C, Oberic L, Gyan E, Pellat-Deceunynck C, Hermine O, Delfau-Larue MH, Tessoulin B, Béné MC, Minvielle S, Le Gouill S. (2020) Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group. Hematol Oncol. 2020 May 29. doi: 10.1002/hon.2750. Sellner L, Schetelig J, Koster L, Choi G, Blaise D, Beelen D, Schianca FC, Passweg J, Schanz U, Gyan E, Sora F, Kröger N, Wulf GG, Van Gorkom G, Mayer J, Orvain C, Bourhis JH, Jindra P, Potter V, Zallio F, Vandenberghe E, Robinson S, Hayden PJ, Yakoub-Agha I, Montoto S, Dreger P; on behalf of the European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties. (2020) Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey. Bone Marrow Transplant 2020 May 22. doi: 10.1038/s41409-020-0946-x Baron M, Belin L, Cassoux N, Fardeau C, Blaizeau M, Soussain C, Houillier C, Hoang-Xuan K, Gyan E, Le Lez ML, Lavaud A, Soubeyran P, Bodaghi B, Costopoulos M, Leblond V, Touitou V, Maloum K, Errera MH, Roos-Weil D, Le Garff-Tavernier M, Choquet S. (2020) Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood, 135:1811-1815 Vallet N, Ertault M, Delaye JB, Chalopin T, Villate A, Drieu La Rochelle L, Lejeune J, Foucault A, Eloit M, Barin-Le Guellec C, Hérault O, Colombat P, Gyan E. (2020) Hypercalcemia is associated with a poor prognosis in lymphoma a retrospective monocentric matched-control study and extensive review of published reported cases. Ann Hematol, 99:229-239 Baron M, Belin L, Cassoux N, Fardeau C, Blaizeau M, Soussain C, Houillier C, Hoang-Xuan K, Gyan E, Le Lez ML, Lavaud A, Soubeyran P, Bodaghi B, Costopoulos M, Leblond V, Touitou V, Maloum K, Errera MH, Roos-Weil D, Le Garff-Tavernier M, Choquet S. (2020) Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood, Mar 2. pii: blood.2019003073. doi: 10.1182/blood.2019003073 Houillier C, Soussain C, Ghesquières H, Soubeyran P, Chinot O, Taillandier L, Lamy T, Choquet S, Ahle G, Damaj G, Agapé P, Moluçon-Chabrot C, Amiel A, Delwail V, Fabbro M, Jardin F, Chauchet A, Moles-Moreau MP, Morschhauser F, Casasnovas O, Gressin R, Fornecker LM, Abraham J, Marolleau JP, Tempescul A, Campello C, Colin P, Tamburini J, Laribi K, Serrier C, Haioun C, Chebrek S, Schmitt A, Blonski M, Houot R, Boyle E, Bay JO, Oberic L, Tabouret E, Waultier A, Martin-Duverneuil N, Touitou V, Cassoux N, Kas A, Mokhtari K, Charlotte F, Alentorn A, Feuvret L, Le Garff-Tavernier M, Costopoulos M, Mathon B, Peyre M, Delgadillo D, Douzane H, Genet D, Aidaoui B, Hoang-Xuan K, Gyan E. (2020) Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology, 94:e1027-e1039 Hueso T, Gastinne T, Garciaz S, Tchernonog E, Delette C, Casasnovas RO, Durot E, Houot R, Tessoulin B, Tournilhac O, Malak S, Gyan E, Fornecker LM, Abraham J, Delapierre B, Peyrade F, Lemal R, Gressin R, Chantepie S, Borel C, Morello R, Bouabdallah K, Ibrahim A, Bouabdallah R, Le Gouill S, Damaj G. (2020) Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. Bone Marrow Transplant. 2020 Jan 17. doi: 10.1038/s41409-020-0783-y Bailly C, Carlier T, Berriolo-Riedinger A, Casasnovas O, Gyan E, Meignan M, Moreau A, Burroni B, Djaileb L, Gressin R, Devillers A, Lamy T, Thieblemont C, Hermine O, Kraeber-Bodéré F, Le Gouill S, Bodet-Milin C. (2020) Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. Haematologica, 105:e33-e36 Dufour C, Foulon S, Geoffray A, Masliah-Planchon J, Figarella-Branger D, Guerrini-Rousseau L, Faure-Conter C, Icher C, Bertozzi AI, Leblond P, Akbaraly T, Bourdeaut F, André N, Chappé C, Schneider P, De Carli E, Chastagner P, Berger C, Lejeune J, Soler C, Entz-Werlé N, Delisle MB. (2020) Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5. Neuro Oncol 2020 Dec 30:noaa301. doi: 10.1093/neuonc/noaa301. Le Louet S, Barkaoui MA, Miron J, Galambrun C, Aladjidi N, Chastagner P, Kebaili K, Armari-Alla C, Lambilliotte A, Lejeune J, Moshous D, Della Valle V, Sileo C, Ducou Le Pointe H, Chateil JF, Renolleau S, Piloquet JE, Portefaix A, Epaud R, Chiron R, Bugnet E, Lorillon G, Tazi A, Emile JF, Donadieu J, Héritier S. (2020) Childhood Langerhans cell histiocytosis with severe lung involvement: a nationwide cohort study. Orphanet J Rare Dis. 2020 Sep 9;15(1):241. doi: 10.1186/s13023-020-01495-5. Pondrom M, Pariente D, Mallon B, Taque S, Branchereau S, Chardot C, Laithier V, Tabone MD, Lejeune J, Faure-Conter C, Saumet L, Vérité C, Aerts I, Brugières L, Fresneau B. (2020) Tumor rupture in hepatoblastoma: A high risk factor? Pediatr Blood Cancer. 2020 Sep;67(9):e28549. doi: 10.1002/pbc.28549. Lejeune J, Chevalier S, Fouquereau E, Chenevert D, Coillot H, Binet A, Gillet N, Mokounkolo R, Michon J, Dupont S, Rachieru P, Gandemer V, Colombat P. (2020) Relationships Between Managerial and Organizational Practices, Psychological Health at Work, and Quality of Care in Pediatric Oncology. JCO Oncol Pract, 16:e1112-e1119 2019 Picou F*, Vignon C*, Debeissat C, Lachot S, Kosmider O, Gallay N, Foucault A, Estienne MH, Ravalet N, Bene MC, Domenech J, Gyan E, Fontenay M, Herault O. (2019) Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Adv, 3: 4271-4279, *equal contributors Chalopin T, Vallet N, Arbion F, Barin C, Rault E, Villate A, Eloit M, Drieu La Rochelle L, Foucault A, Ertault M, Dartigeas C, Benboubker L, Estienne MH, Domenech J, Herault O, Gyan E. (2019) Characteristics, combinations, treatments, and survival of second primary hematological neoplasm: a retrospective single-center cohort of 49 patients (Hemo2 study). Ann Hematol, 98:2367-2377 Gyan E, Almeida AM. (2019) Less iron improves MDS haematopoiesis. Br J Haematol, 187:11-12 Brachet-Botineau M, Deynoux M, Vallet N, Polomski M, Juen L, Herault O, Mazurier F, Viaud-Massuard MC, Prié G, Gouilleux F. (2019) A novel inhibitor of STAT5 signaling overcomes chemotherapy resistance in myeloid leukemia cells. Cancers (Basel), 11: pii: E2043. Lanznaster D, Bourgeais J, Bruno C, Hergesheimer RC, Thepault R-A, Vourc’h P, Corcia P, Andres CR, Herault O*, Blasco H*. (2019) TDP-43-mediated toxicity in HEK293T cells: a fast and reproducible protocol to be employed in the search of new therapeutic options against amyotrophic lateral sclerosis. Cells, 9:68 *equal contributors Leveque X, Hochane M, Geraldo F, Dumont S, Gratas C, Oliver L, Gaignier C, Trichet V, Heymann D, Herault O, Vallette FM, Olivier C. (2019) Low-dose pesticide mixture induces accelerated mesenchymal stem cells aging. Stem Cells, 37:1083-1094 Chabi S, Uzan B, Naguibneva I, Rucci J, Fahy L, Calvo J, Arcangeli ML, Mazurier F, Pflumio F, Haddad R. (2019) Hypoxia regulates lymphoid development of human hematopoietic progenitors. Cell Rep, 29:2307-2320 Paris J, Morgan M, Campos J, Spencer GJ, Shmakova A, Ivanova I, Mapperley C, Lawson H, Wotherspoon DA, Sepulveda C, Vukovic M, Allen L, Sarapuu A, Tavosanis A, Guitart AV, Villacreces A, Much C, Choe J, Azar A, van de Lagemaat LN, Vernimmen D, Nehme A, Mazurier F, Somervaille TCP, Gregory RI, O'Carroll D, Kranc KR. (2019) Targeting the RNA m6A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. Cell Stem Cell, 25:137-148 Ibrahim S, Dakik H, Vandier C, Chautard R, Paintaud G, Mazurier F, Lecomte T, Guéguinou M, Raoul W. (2019) Expression profiling of calcium channels and calcium-activated potassium channels in colorectal cancer. Cancers (Basel). 2019 Apr 19;11(4). pii: E561. doi: 10.3390/cancers11040561. Zebian A, Shaito A, Mazurier F, Rezvani HR, Zibara K. (2019) XPC beyond nucleotide excision repair and skin cancers. Mutat Res. 2019 Oct - Dec;782:108286. doi: 10.1016/j.mrrev.2019.108286. Review Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N , Lefebvre T, Karim Z, Alary AS, Rousseau A, Bouilloux C, Ducamp S, Verdier F, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Ame S, Rose C, Lachenal F, Toma A, Pica JM, Carre M, Garban F, Pegourie B, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Fontenay M, Dreyfus F. (2019) Dyserythropoiesis evaluated by Red Score and hepcidin/ferritin levels predicts response to epoetin zeta in lower risk MDS. Haematologica, 104:497-504 Jaimes-Albornoz D, Mannone L, Nguyen-Quoc S, Chalandon Y, Chevallier P, Mohty M, Meunier M, Robin M, Ledoux MP, Guillerm G, Bay JO, Poiré X, Maillard N, Leclerc M, Daguindau E, Beguin Y, Rubio MT, Gyan E. (2019) Allogeneic stem cell transplantation in therapy-related myelodysplasia after autologous transplantation for lymphoma: A retrospective study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Biol Blood Marrow Transplant, 25:2366-2374 Gyan E, Derkyi-Kwarteng L, Brown AA, Derkyi-Kwarteng A, Darkwa AA, Quayson S, Akakpo PK. (2019) Benign breast conditions: An eight-year single-centre histopathological review of women presenting with mass lesions at the Korle-Bu Teaching Hospital, Ghana. Ann Diagn Pathol 42:33-38 Bondu S, Alary AS, Lefèvre C, Houy A, Jung G, Lefebvre T, Rombaut D, Boussaid I, Bousta A, Guillonneau F, Perrier P, Alsafadi S, Wassef M, Margueron R, Rousseau A, Droin N, Cagnard N, Kaltenbach S, Winter S, Kubasch AS, Bouscary D, Santini V, Toma A, Hunault M, Stamatoullas A, Gyan E, Cluzeau T, Platzbecker U, Adès L, Puy H, Stern MH, Karim Z, Mayeux P, Nemeth E, Park S, Ganz T, Kautz L, Kosmider O, Fontenay M. (2019) A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. Sci Transl Med 11(500) Ternant D, Monjanel H, Venel Y, Prunier-Aesch C, Arbion F, Colombat P, Paintaud G, Gyan E. (2019) Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: a pilot study. Br J Clin Pharmacol, 85:2002-2010 Cornillon J, Daguenet E, Bay JO, Chauchet A, Salles G, Contentin N, Nicolas-Virelizier E, Mercier M, Vallet N, Alexis M, Chrétien ML, Cluzeau T, Huynh A, Himberlin C, Dorvaux V, Amorim S, Lejeune C, de Latour RP, Gyan E. (2019) BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Ann Hematol, 98:1973-1980 Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi JM. (2019) Etiology and outcomes of thrombotic microangiopathies. Clin J Am Soc Nephrol, 14:557-566 Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; Intergroupe GOELAMS–ANOCEF; LOC Network for CNS Lymphoma. (2019) Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol, 37:823-833 Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, Chermat F, Sapena R, Nibourel O, Chaffaut C, Chevret S, Preudhomme C, Adès L, Fenaux P. (2019) A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica, 104:1565-1571 Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C. (2019) Lenalidomide in Combination with Intravenous Rituximab (REVRI) in Relapsed/Refractory Primary CNS Lymphoma or Primary Intraocular Lymphoma: a Multicenter Prospective "Proof of Concept" Phase II Study of the French Oculo-Cerebral Lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). Ann Oncol, 30:621-628 2018 Picou F, Debeissat C, Bourgeais J, Gallay N, Ferrié E, Foucault A, Ravalet N, Maciejewski A, Vallet N, Ducrocq E, Haddaoui L, Domenech J, Hérault O*, Gyan E*. (2018) n-3 Polyunsaturated fatty acids induce acute myeloid leukemia cell death associated with mitochondrial glycolytic switch and Nrf2 pathway activation. Pharmacol Res, 136:45-55 *equal contributors Girerd S, Tosca L, Herault O, Vignon C, Biard D, Aggoune D, Dkhissi F, Bonnet ML, Sorel N, Desterke C, Bennaceur Griscelli A, Tachdjian G, Guilhot F, Guilhot J, Chomel JC, Turhan AG. (2018) Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells. Biochem Biophys Res Commun, 498:715-722 Gyan E, Raynard B, Durand JP, Lacau Saint Guily J, Gouy S, Movschin ML, Khemissa F, Flori N, Oziel-Taieb S, Bannier Braticevic C, Zeanandin G, Hebert C, Savinelli F, Goldwasser F, Hébuterne X; NutriCancer 2012 Investigator Group. (2018) Malnutrition in patients with cancer. J Parenter Enteral Nutr, 42:255-260 Oyallon B, Brachet-Botineau M, Logé C, Bonnet P, Souab M, Robert T, Ruchaud S, Bach S, Berthelot P, Gouilleux F, Viaud-Massuard MC, Denevault-Sabourin C. (2018) Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors. Eur J Med Chem, 154:101-109 Voeltzel T, Flores-Violante M, Zylbersztejn F, Lefort S, Billandon M, Jeanpierre S, Joly S, Fossard G, Milenkov M, Mazurier F, Nehme AH, Belhabri A, Paubelle E, Thomas X, Michallet M, Louache F, Nicolini FE, Caron de Fromentel C, Maguer-Satta V. (2018) A new signaling cascade linking BMP4, BMPR1A, ΔNp73 and NANOG impacts on stem-like human cell properties and patient outcome. Cell Death & Dis, 9:1011 Rose C, Lenoir C, Gyan E, Hacini M, Amé S, Corront B, Beyne-Rauzy O, Adiko D, Loppinet E, Ali-Ammar N, Laribi K, Wattel E, Dreyfus F, Roué CS, Cheze S. (2018) Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload. Eur J Haematol. 2018 May 2. doi: 10.1111/ejh.13088. Daix T, Guérin E, Tavernier E, Mercier E, Gissot V, Herault O, Mira JP, Dumas F, Chapuis N, Guitton C, Bene MC, Quenot JP, Tissier C, Guy J, Piton G, Roggy A, Muller G, Legac E, de Prost N, Khellaf M, Wagner Ballon O, Coudroy R, Dindinaud E, Uhel F, Roussel M, Lafon T, Jeannet R, Vargas F, Fleureau C, Roux M, Allou K, Vignon P, Feuillard J, François B for the Septiflux trial group. (2018) Multicentric standardized flow cytometry routine assessment of septic patient to predict clinical worsening. Chest, 154:617-627 Zibara K, Zeidan A, Mallah K, Kassem N, Awad A, Mazurier F, Badran B, El-Zein N. (2018) Signaling pathways activated by PACAP in MCF-7 breast cancer cells. Cell Signal, 50:37-47 Le Nail LR, Brennan M, Rosset P, Deschaseaux F, Piloquet P, Pichon O, Le Caignec C, Crenn V, Layrolle P, Herault O, De Pinieux G, Trichet V. (2018) Comparison of tumor- and bone marrow-derived mesenchymal stromal/stem cells from patients with high-grade osteosarcoma. Int J Mol Sci, 19 pii: E707. doi: 10.3390/ijms19030707 Ponard A, Ferreira-Maldent N, Ertault M, Delain M, Amraoui K, Regina S, Jonville-Bera AP, Herault O, Colombat P, Gyan E. (2018) Glycemic dysregulation in a patient with type 2 diabetes treated with 5-azacitidine: a case report. J Med Case Rep, 12:199 Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. (2018) Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N Engl J Med 379:934-947 Pernot B, Gyan E, Maillot F, Hodges P, Ertault M, Ferreira-Maldent N. (2018) Lymphomas diagnosed in an internal medicine department compared to lymphomas diagnosed in other departments: Clinical and outcome differences. Medicine (Baltimore), 97:e13228 Díez-Campelo M, Lorenzo JI, Itzykson R, Rojas SM, Berthon C, Luño E, Beyne-Rauzy O, Perez-Oteyza J, Vey N, Bargay J, Park S, Cedena T, Bordessoule D, Muñoz JA, Gyan E, Such E, Visanica S, López-Cadenas F, de Botton S, Hernández-Rivas JM, Ame S, Stamatoullas A, Delaunay J, Salanoubat C, Isnard F, Guieze R, Pérez Guallar J, Badiella L, Sanz G, Cañizo C, Fenaux P. (2018) Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries. Br J Haematol, 181:350-359 Lacau St Guily J, Bouvard É, Raynard B, Goldwasser F, Maget B, Prevost A, Seguy D, Romano O, Narciso B, Couet C, Balon JM, Vansteene D, Salas S, Grandval P, Gyan E, Hebuterne X. (2018) NutriCancer: A French observational multicentre cross-sectional study of malnutrition in elderly patients with cancer. J Geriatr Oncol, 9:74-80 Gyan E, Sonet A, Brice P, Anglaret B, Laribi K, Fruchart C, Tilly H, Araujo C, Soubeyran P, Gonzalez H, Morineau N, Nicolas-Virelizier E, Ghesquières H, Salles B, Bouabdallah R, Orfeuvre H, Fahri J, Couturier O, Xerri L, Feugier P; Lymphoma Study Association (LYSA). (2018) Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study. Br J Haematol, 188:76-86 Al Tabaa Y, Tchernonog E, Faurie P, Cottereau AS, Monjanel H, Bonnet A, Le Gouill S, Gyan E, Ghesquieres H, Mariano-Goulart D, Cartron G. (2018) Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma. Eur J Nucl Med Mol Imaging, 45:1705-1709 Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G. (2018) A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood, 132:49-58 Fargier E, Ranchon F, Huot L, Guerre P, Safar V, Dony A, Hequet N, Bachy E, Savouroux S, Fronteau C, Tomaré P, Tournamille JF, Schwiertz V, Vantard N, Le Gouill S, Gyan E, Salles G, Rioufol C. (2018) SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. Ann Hematol, 97:123-131 Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Le Bras F, Willems E, Tchernonog E, Chalopin T, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquières H, Tournilhac O, Gomes da Silva M, Bouabdallah R, Salles G, Bachy E. (2018) Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: An analysis of patients from LYSA centers. Ann Oncol, 29:725-723 Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuilliez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V. (2018) R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL). Blood, 131:174-181 Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Benbrahim O, Ugo V, Lippert E, Kiladjian JJ. (2018) Benefits and pitfalls of Peg-Interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis, a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica, 103:438-446 2017 Juen L, Brachet-Botineau M, Parmenon C, Bourgeais J, Herault O, Gouilleux F, Viaud-Massuard MC, Prié G. (2017) A new inhibitor targeting signal transducer and activator of transcription 5 (STAT5) signaling in myeloid leukemias. J Med Chem, 60:6119-6136 Desbourdes L, Javary J, Charbonnier T, Ishac N, Bourgeais J, Iltis A, Chomel JC, Turhan A, Guilloton F, Tarte K, Demattei MV, Ducrocq E, Rouleux-Bonnin F, Gyan E, Herault O, Domenech J. (2017) Alteration analysis of bone marrow mesenchymal stromal cells from de novo acute myeloid leukemia patients at diagnosis. Stem Cell Dev, 26:709-722 Ghanem S, Friedbichler K, Boudot C, Bourgeais J, Gouilleux-Gruart V, Regnier V, Herault O, Moriggl R, Gouilleux F. (2017) STAT5A/5B-specific expansion and transformation of hematopoietic stem cells. Blood Cancer J, 7:e514 Bourgeais J, Ishac N, Medrzycki M, Brachet-Botineau M, Desbourdes L, Gouilleux-Gruart V, Pecnard E, Rouleux-Bonnin F, Gyan E, Domenech J, Mazurier F, Moriggl R, Bunting KD, Herault O, Gouilleux F. (2017) Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses. Oncotarget, 8:41876-41889 Veyrat-Durebex C, Debeissat C, Blasco H, Patin F, Henique H, Emond P, Antar C, Gissot V, Maillot F*, Herault O*. (2017) Phenylalanin plasma concentration is correlated with global decrease of antioxidant genes expression in adult PKU patients. JIMD Rep, 37:73-83 *equal contributors Raynard B, Hébuterne X, Goldwasser F, Ait Hssain A, Dubray Longeras P, Barthélémy P, Rosso E, Phoutthasang V, Bories C, Digue L, Laharie D, Desport JC, Falkowski S, Lacau Saint Guily J, Gyan E. (2017) Crossed perceptions about malnutrition in patients and their doctors in oncology. Bull Cancer, 104:921-928 Aggoune D, Sorel N, Bonnet ML, Goujon JM, Tarte K, Hérault O, Domenech J, Réa D, Legros L, Johnson-Ansa H, Rousselot P, Cayssials E, Guerci-Bresler A, Bennaceur-Griscelli A, Chomel JC, Turhan AG. (2017) Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs). Leuk Res, 60:94-102 Chalopin T, Barillot I, Biny JP, Arbion F, Besson M, Santiago-Ribeiro M, Piver E, Herault O, Gyan E, Benboubker L. (2017) Primary solitary plasmacytoma of the liver - successful treatment with fractionated stereotactic radiotherapy (Cyberknife®): a case report. J Med Case Rep, 11:193 Cheloni G, Tanturli M, Tusa I, DeSouza NH, Shan Y, Gozzini A, Mazurier F, Rovida E, Li S, Dello Sbarba P. (2017) Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood, 130:655-666 Nguyen PH, Charbonnier L, Giraud J, Dubus P, Wittkop L, Belleannée G, Collet D, Soubeyran I, Evrard S, Rousseau B, Senant-Dugot N, Mégraud F, Mazurier F, Varon C. (2017) Characterization of biomarkers of tumorigenic and chemoresistant cancer cells in human gastric carcinoma. Clin Cancer Res, 23:1586-1597 Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, Gyan E, Haioun C, Mercier M, Feugier P, Boussetta S, Paintaud G, Ternant D, Cartron G. (2017) Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a LYSA study. Blood, 129:2616-2623 Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, Palama T, Chesnais V, Birsen R, Vergez F, Farge T, Chenevier-Gobeaux C, Fraisse M, Bouillaud F, Debeissat C, Herault O, Recher C, Lacombe C, Fontenay M, Mayeux P, Maciel T, Portais JC, Sarry JE, Tamburini J, Bouscary D, Chapuis N. (2017) High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells. Leukemia, 31:2326-2335 Freund P, Kerenyi M, Hager M, Wagner T, Wingelhofer B, Thi Thanh Pham H, Elabd M, Han X, Valent P, Gouilleux F, Sexl V, Krämer O, Groner B, Moriggl R. (2017) O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies. Leukemia 31:2132-2142 Martinez D, Muhrez K, Woillard JB, Berthelot A, Gyan E, Choquet S, Andrès CR, Marquet P, Barin-Le Guellec C. (2017) Endogenous metabolites-mediated communication between OAT1/OAT3 and OATP1B1 may explain the association between SLCO1B1 SNPs and methotrexate toxicity. Clin Pharmacol Ther, 2017 Dec 29. doi: 10.1002/cpt.1008 Cahu X, Carré M, Recher C, Pigneux A, Hunault-Berger M, Vey N, Chevallier P, Delaunay J, Gyan E, Lioure B, Bonmati C, Himberlin C, Hichri Y, Guillerm G, Bouscary D, Larosa F, Ojeda-Uribe M, Bernard M, Béné MC, Ifrah N, Cahn JY. (2017) Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia. Eur J Haematol, 98:443-449 Damaj G, Cornillon J, Bouabdallah K, Gressin R, Vigouroux S, Gastinne T, Ranchon F, Ghésquières H, Salles G, Yakoub-Agha I, Gyan E. (2017) Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. Bone Marrow Transplant, 52:941-949 Gauthier J, Castagna L, Garnier F, Guillaume T, Socié G, Maury S, Maillard N, Tabrizi R, Marchand T, Malfuson J, Gac A, Gyan E, Mercier M, Béguin Y, Delage J, Turlure P, Marçais A, Nguyen S, Dulery R, Bay J, Huynh A, Daguindau E, Cornillon J, Régny C, Michallet M, Peffault de Latour R, Yakoub-Agha I, Blaise D. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplant, 52:689-696 Tchernonog E, Faurie P, Coppo P, Monjanel H, Bonnet A, Algarte Génin M, Mercier M, Dupuis J, Bijou F, Herbaux C, Delmer A, Fabiani B, Besson C, Le Gouill S, Gyan E, Laurent C, Ghesquieres H, Cartron G. (2017) Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the Lysa group. Ann Oncol, 28:843-848 Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ. (2017) Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials. J Clin Oncol, 35:552-560 Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K. (2017) Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro Oncol, 19:422-429 Aspeslagh S, Stein M, Bahleda R, Hollebecque A, Salles G, Gyan E, Fudio S, Extremera S, Alfaro V, Soto-Matos A, Soria JC. (2017) Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. Anticancer Drugs, 28:341-349 Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P. (2017) Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. Lancet Haematol, 4:e35-e45 Sébert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Adès L. (2017) Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. Leuk Res, 63:72-77 2016 Bourgeais J*, Bustany S*, Tchakarska G, Body S, Herault O, Gouilleux F, Sola B. (2016) Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells. Oncotarget, 7:45214-45224 *equal contributors Bire S, Ishac N, Rouleux-Bonnin F. (2016) In vitro synthesis, delivery, and bioavailability of exogenous mRNA in gene transfer mediated by PiggyBac transposition. Methods Mol Biol 1428:187-217 Bastie C, Rouleux-Bonnin F. DNA elements tetris: a Strategy for gene correction. In: Modern Tools for Genetic Engineering. Edited by Michael S.D. Kormann. InTech, Rijeka, Croatia, 2016 http://dx.doi.org/10.5772/62382 Domenech J. What are MSCs? Origin and discovery of mesenchymal stromal cells (MSCs). In: Mesenchymal stromal cells as tumor stromal modulators. Edited by Garcia & Bolontrade. Academic Press/Elsevier Science, Amsterdam, Pays-Bas, 2016, pages 1-37 Deynoux M, Sunter N, Hérault O, Mazurier F. (2016) Hypoxia and hypoxia-inducible factors in leukemia's. Front Oncol 6:41 Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P, Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry. (2016) Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. Br J Haematol, 175:975-979 Zhang Y, Dépond M, He L, Foudi A, Kwarteng E, Lauret E, Plo I, Desterke C, Dessen P, Fujii N, Opolon P, Herault O, Solary E, Vainchenker W, Joulin V, Louache F, M Wittner M. (2016) CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress. Sci Rep 6:37827 Themmans M, Mueller KM, Kessler SM, Golob-Schwarzl N, Mohr T, Kaltenecker D, Bourgeais J, Paier-Pourani J, Friedbichler K, Schneller D, Schlederer M, Zebedin-Brandl E, Terracianno LM, Han X, Kenner L, Wagner K, Mikulits W, Kozlov AV, Heim MH, Gouilleux F, Haybaeck J, Moriggl R. (2016) Hepatic deletion of Janus Kinase 2 counteracts oxidative stress in mice. Sci Rep, 6:34719 Brachet G, Bruno C, Boulay D, Tournamille JF, Gyan E, Viaud-Massuard MC, Respaud R. (2016) An ion-pairing, reversed-phase liquid chromatography method to assess the cross-contamination of cancer chemotherapy infusions prepared in a dual-operator aseptic isolator. Drug Test Anal Drug Test Anal, 8:985-90 Lioger B, Ferreira-Maldent N, Cottier JP, Debiais S, Gyan E, Maillot F. (2016) Rituximab for Sjögren syndrome-associated type II mixed cryoglobulinemic cerebral vasculitis. Neurol Neuroimmunol Neuroinflamm, 3:e253 Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T, Fornecker LM, Garidi R, Tricot S, Houot R, Joly B, Abarah W, Choufi B, Pham AD, Gac AC, Fruchart C, Marin E, Safar V, Parcelier A, Maisonneuve H, Bachy E, Cartron G, Jaccard A, Tournilhac O, Rossi C, Schirmer L, Martignoles JA, Gaulard P, Tilly H, Damaj G, Lymphoma Study Association Lysa Centers. (2016) Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. Oncotarget, 7:85573-85583 Tixier F, Ranchon F, Iltis A, Vantard N, Schwiertz V, Bachy E, Bouafia-Sauvy F, Sarkozy C, Tournamille JF, Gyan E, Salles G, Rioufol C. (2016) Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients. Hematol Oncol, 2016 Jul 5. doi: 10.1002/hon.2328 Chandesris MO, Damaj G, Canioni D, Brouzes C, Lhermitte L, Hanssens K, Frenzel L, Cherquaoui Z, Durieu I, Durupt S, Gyan E, Beyne-Rauzy O, Launay D, Faure C, Hamidou M, Besnard S, Diouf M, Schiffmann A, Niault M, Jeandel PY, Ranta D, Gressin R, Chantepie S, Barete S, Dubreuil P, Bourget P, Lortholary O, Hermine O; CEREMAST Study Group. (2016) Midostaurin in advanced systemic mastocytosis. N Engl J Med, 374:2605-2607 Murhez K, Benz-de Bretagne I, Nadal-Desbarats L, Blasco H, Gyan E, Choquet S, Montigny F, Emond P, Barin-Le Guellec C. (2016) Endogenous metabolites that are substrates of Organic Anion Transporter's (OATs) predict methotrexate clearance. Pharmacol Res, 118:121-132 Chaumier F, Gyan E, Vallet N, Hérault B, Mallet D.(2016) Acute Myeloblastic Leukemia in the Elderly: How Could Palliative Care Teams and Hematologists Better Work Together? J Palliat Med, 9:906-907 Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R. (2016) Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol, 18:1297-1303 Gac AC, Azar N, Daguindau E, Cartron G, Fornecker LM, Gyan E, Broussais-Guillaumot F, Garidi R, Choufi B, Chantepie SP, Béné MC, Guiéze R, Bijou F, Gressin R, Amorim S, Damaj G. (2016) Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases. Leuk Lymphoma, 57:1149-1153 Desoubeaux G, Cabanne É, Franck-Martel C, Gombert M, Gyan E, Lissandre S, Renaud M, Monjanel H, Dartigeas C, Bailly É, Van Langendonck N, Chandenier J. (2016) Pulmonary toxoplasmosis in immunocompromised patients with interstitial pneumonia: a single-centre prospective study assessing PCR-based diagnosis. J Clin Pathol, 69:726-730 Doyen H, Monjanel H, Regina S, Magnant J, Arbion F, Lissandre S, Gyan E, Le Lez ML. (2016) A case of chorioretinopathy as first manifestation of Hodgkin's lymphoma. Retin Cases Brief Rep, 10:239-243 Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Makhoul PC, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F. (2016) Lenalidomide with or without erythropoietin in transfusion dependent erythropoiesis-stimulating agent-refractory lower risk MDS without 5q deletion. Leukemia, 30:897-905 2015 Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, Del Rio MS, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy ML, Hoang-Xuan K. (2015) Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol 2:e251-9 (IF2015=4,889) Hosseini M, Mahfouf W, Serrano-Sanchez M, Raad H, Harfouche G, Bonneu M, Claverol S, Mazurier F, Rossignol R, Taieb A, Rezvani HR. (2014) Premature Skin Aging Features Rescued by Inhibition of NADPH Oxidase Activity in XPC-Deficient Mice. J Invest Dermatol, 135:1108-1118 (IF2015=6,915)
Carvalhosa AB, Aouba A, Damaj G, Canioni D, Brouzes C, Gyan E, Durupt S, Durieu I, Cathebras P, Costédoat-Chalumeau N, Launay D, Pilmis B, Barete S, Frenzel L, Lortholary O, Hermine O, Hermans C, Chandesris MO. (2015) A French national survey on clotting disorders in mastocytosis. Medicine (Baltimore) 94:e1414 (IF2015=2,133)
Lazarovici J, Dartigues P, Brice P, Obéric L, Gaillard I, Hunault-Berger M, Broussais-Guillaumot F, Gyan E, Bologna S, Nicolas-Virelizier E, Touati M, Casasnovas O, Delarue R, Orsini-Piocelle F, Stamatoullas A, Gabarre J, Fornecker LM, Gastinne T, Peyrade F, Roland V, Bachy E, André M, Mounier N, Fermé C. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. Haematologica, 100:1579-86 (IF2015=6,671) Gatault P, Brachet G, Ternant D, Degenne D, Récipon G, Barbet C, Gyan E, Gouilleux-Gruart V, Bordes C, Farrell A, Halimi JM, Watier H. (2015) Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule. MAbs, 7:1205-1211 (IF2015=4,161)
Gautier J, Allard-Vannier E, Burlaud-Gaillard J, Domenech J, Chourpa I. (2015) Efficacy and hemotoxicity of stealth doxorubicin-loaded magnetic nanovectors on breast. cancer xenografts. J Biomed Nanotechnol, 11:177-189 (IF2015=3,929) Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris MO, Elie C, Hamidou M, Durieu I, Suarez F, Grosbois B, Limal N, Gyan E, Larroche C, Guillet G, Kahn JE, Casassus P, Amazzough K, Coignard-Biehler H, Georgin-Lavialle S, Lhermitte L, Fraitag S, Canioni D, Dubreuil P, Hermine O. (2015) Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood 126:1009-1016 (IF2015=11,847) Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P; European ALMA Investigators. (2015) Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. Leuk Res, 39:296-306 (IF2015=2,606) Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, Sibon D, Thieblemont C, Dupuis J, Terrier B, Feray C, Tilly H, Pol S, Leblond V, Settegrana C, Rabiega P, Barthe Y, Hendel-Chavez H, Nguyen-Khac F, Merle-Béral H, Berger F, Molina T, Charlotte F, Carrat F, Davi F, Hermine O, Besson C; ANRS HC-13 Lympho-C Study Group. (2015) Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol, 90:197-203 (IF2015=5,000) Lafia E, Anani L, Glitho S, Bankole C, Fachinan H, Py JY, Domenech J, Martenot B, Colombat P, Chobli M, Zohoun I. (2015) North-South cooperation on transfusion and hematology teaching: A Benin experience. Transfus Clin Biol, 22:80-82 (IF2015=0,561) Guièze R, Gyan E, Tournilhac O, Halty C, Veyrat-Masson R, Akil S, Berger M, Hérault O, Callanan M, Bay JO. (2015) Docosahexaenoic acid induces apoptosis in primary chronic lymphocytic leukemia cells. Hematol Rep 7:6043 Gyan E, Dreyfus F, Fenaux P. (2015) Refractory thrombocytopenia and neutropenia: a diagnostic challenge. Mediterr J Hematol Infect Dis. 7(1):e2015018 2014 Berger A, Hoelbl-Kovacic A, Bourgeais J, Hoefling L, Warsch W, Grundschober E, Uras I, Menzl I, Putz E, Hoermann G, Schuster C, Fajmann S, Leitner E, Kubicek S, Moriggl R, Gouilleux F, Sexl V. (2014) PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. Leukemia 28:629-641 (IF2014=10,431) Chaigne B, Dartigeas C, Benboubker L, Chaumier F, Ertault M, Lissandre S, Stacoffe M, Maillot F, Blasco H, Vourc'h P, Colombat P, Gyan E. (2014) Could a citrus keep the hematologist away? Br J Haematol, 166:298-300 (IF2014=4,971) Guilleminault L, Azzopardi N, Arnoult C, Sobilo J, Hervé V, Montharu J, Guillon A, Andres C, Herault O, Le Pape A, Diot P, Lemarié E, Paintaud G, Gouilleux-Gruart V, Heuzé-Vourc'h N. (2014) Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J Control Release, 196C:344-354 (IF2014=7,705) Herr F, Lemoine R, Gouilleux F, Meley D, Kazma I, Heraud A, Velge-Roussel F, Baron C, Lebranchu Y. (2014) IL-2 phosphorylates STAT5 to drive IFN-γ production and activation of human dendritic cells. J Immunol, 192:5660-5670 (IF2014=4,922) Le Nail LR, Stanovici J, Fournier J, Splingard M, Domenech J, Rosset P. (2014) Percutaneous grafting with bone marrow autologous concentrate for open tibia fractures: analysis of forty three cases and literature review. Int Orthop 38:1845-1853 (IF2014=2,110) Desoubeaux G, Franck-Martel C, Bailly E, Le Brun C, Gyan E, Goudeau A, Chandenier J, Lanotte P. (2014) Prospective assessment of FilmArray® technology for the rapid identification of yeast isolated from blood cultures. J Microbiol Meth, 106C:119-122 (IF2014=2,026) Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J, Pigneux A, Schiller GJ, Jung J, Jane Leonard E, Fingert H, Westervelt P. (2014) An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. Leuk Res Rep 3:58-61 Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G, Le Gouill S, Haioun C, Tarte K, Lamy T, Milpied N, Fest T; for the Groupe Ouest-Est des Leucémies et Autres Maladies du Sang. (2014) High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia 28:2367-2375 (IF2014=10,431) Cornet E, Tomowiak C, Tanguy-Schmidt A, Lepretre S, Dupuis J, Feugier P, Devidas A, Mariette C, Leblond V, Thiéblemont C, Validire-Charpy P, Sutton L, Gyan E, Eisenmann JC, Cony-Makhoul P, Ysebaert L, Troussard X; on the behalf of the Société Française d'Hématologie. (2014) Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. Br J Haematol, 166:390-400 (IF2014=4,971) Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D, Kolb B, Durieu I, Gyan E, Livideanu C, Chèze S, Diouf M, Garidi R, Georgin-Lavialle S, Asnafi V, Lhermitte L, Lavigne C, Launay D, Arock M, Lortholary O, Dubreuil P, Hermine O. (2014) ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One, 9:e85362 (IF2014=3,234) Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K, Thieblemont C, Cacheux V, Cartron G, Compain L, Gyan E, Morschhauser F, Casasnovas O, Moles MP, Michallet AS, Gressin R, Damaj G, Rose C, Sirvent A, Hermine O, Mohty M, Milpied N, Le Gouill S. (2014) Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Ann Hematol, 93:233-242 (IF2014=2,634) Benz-de Bretagne I, Zahr N, Le Gouge A, Hulot JS, Houillier C, Hoang-Xuan K, Gyan E, Lissandre S, Choquet S, Le Guellec C. (2014) Urinary coproporphyrin I/(I+III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance. Br J Clin Pharmacol, 78:329-342 (IF2014=3,878) Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators. (2014) A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol, 167:466-77 (IF2014=4,971) Kofman T, Zhang SY, Copie-Bergman C, Moktefi A, Raimbourg Q, Francois H, Karras A, Plaisier E, Painchart B, Favre G, Bertrand D, Gyan E, Souid M, Roos-Weil D, Desvaux D, Grimbert P, Haioun C, Lang P, Sahali D, Audard V. (2014) Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders: a retrospective study of 18 cases. Medicine, 93:350-358 (IF2014=5,723) 2013 Rouault-Pierre K, Lopez-Onieva L, Foster K, Anjos-Afonso F, Lamrissi-Garcia I, Serrano-Sanchez M, Mitter R, Ivanovic Z, de Verneuil H, Gribben J, Taussig D, Rezvani HR, Bonnet D*, Mazurier F*. (2013) HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress. Cell Stem Cell, 13:549-563 *equal contributors (IF 2013=25,911) Bire S, Ley D, Casteret S, Mermod N, Bigot Y, Rouleux-Bonnin F. (2013) Optimization of the piggyBac transposon using mRNA and insulators: Toward a more reliable gene delivery system. PLoS One, 8:e82559 (IF2013=3,534) Bire S, Gosset D, Jégot G, Midoux P, Pichon C, Rouleux-Bonnin F. (2013) Exogenous mRNA delivery and bioavailability in gene transfer mediated by piggyBac transposition. BMC Biotechnol, 13:75 (IF2013=2,592) Bourgeais J, Gouilleux-Gruart V, Gouilleux F. (2013) Oxidative metabolism in Cancer: a STAT affair ? JAK-STAT, 2:e25764 1-8 (revue) Vignon C, Debeissat C, Georget MT, Bouscary D, Gyan E, Rosset P, Herault O. (2013) Flow cytometric quantification of all phases of the cell cycle and apoptosis in a two-color fluorescence plot. PLoS One, 8:e68425 1-8 (IF2013=3,534) Bire S, Rouleux-Bonnin F. (2013) Transgene site-specific integration: problems and solutions. Top Curr Genet. 2013, 23:3-39 (revue) Francia T, Hanna J, Herault O. (2013) Contribution of the polyvalent medical laboratory in the exploration of leukocytosis. Immuno-Anal Biol Spe, 28:216-222 (IF2013=0,112) Ley D, Harraghy N, Le Fourn V, Bire S, Girod PA, Regamey A, Rouleux-Bonnin F, Bigot Y, Mermod N. (2013) MAR elements and transposons for improved transgene integration and expression. PLoS One, 8:e62784 (IF2013=3,534) Radesi-Sarghi S, Arbion F, Dartigeas C, Delain M, Benboubker L, Herault O, Colombat P, Gyan E. (2013) Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years' experience in a single centre. Ann Hematol. 2013 Nov 14 (IF2013=2,396) Quéré P, Pierre J, Hoang MD, Esnault E, Domenech J, Sibille P, Dimier-Poisson I. (2013) Presence of dendritic cells in chicken spleen cell preparations and their functional interaction with the parasite Toxoplasma gondii. Vet Immunol Immunopathol, 153:57-69 (IF 2013=1,748) Respaud R, Quenuma L, Plichon C, Tournamille JF, Gyan E, Antier D, Viaud-Massuard MC. (2013) A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids. J Pharm Biomed Anal, 83:164–170 (IF2013=2,829) Gyan E, Damotte D, Courby S, Sénécal D, Quittet P, Schmidt A , Banos A, Le Gouill S, Lamy T, Fontan J, Maisonneuve H, Alexis A, Dreyfus F, Tournilhac O, Laribi K, Solal-Céligny P, Arakelyan N, Cartron G, Gressin R, on behalf of the GOELAMS study. (2013) High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, 4 ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first 5 relapse: results of the R-NIMP GOELAMS study. Br J Haematol, 162:240-249 (IF2013=4,959) Ianotto JC, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, De Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Schoenwald M, Andreoli A, Abgrall JF, Kiladjian JJ. (2013) Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol, 162:783-791 (IF2013=4,959) Salles GA, Morschhauser F, Solal-Céligny P, Thieblemont C, Lamy T, Tilly H, Gyan E, Lei G, Wenger M, Wassner-Fritsch E, Cartron G. (2013) Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol, 31:2920-2926 (IF2013=17,960) Pascal L, Beyne-Rauzy O, Brechignac S, Marechaux S, Vassilieff D, Ernst O, Berthon C, Gyan E, Gourin MP, Dreyfus F, Fenaux P, Rose C. (2013) Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. Br J Haematol, 162:413-415 (IF2013=4,959) Trebouet A, Marchand T, Lemal R, Gyan E, Broussais-Guillaumot F, Guillermin Y, Monjanel H, Salles G, Le Gouill S, Godmer P, Fruchart C, Damaj G, Feugier P, Thieblemont C, Maynadié M, Monnereau A, Troussard X, Rossille D, Lamy T, Houot R. (2013) Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. Ann Oncol, 24:2612-2618 (IF2013=6,578) Pessis R, Bahé L, Gyan E, Zakine G, Atlan M. (2013) Occult Primary MALT lymphoma of the breast diagnosed and treated by reduction mammaplasty. An exceptional case report and review of the literature. Ann Chir Plast Esthet, 58:684-687 Ghesquières H, Stamatoullas A, Casasnovas O, Morschhauser F, Gyan E, Gabarre J, Malphettes M, Clément L, Ferlay C, Brice P. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leuk Lymphoma, 54:2399-2404 (IF2013=2,605) Khellaf M, Vialard JF, Hamidou M, Cheze S, Roudot-Thoraval F, Lefrere F, Fain O, Audia S, Abgrall JF, Michot JM, Dauriac C, Lefort S, Gyan E, Niault M, Durand JM, Languille L, Boutboul D, Bierling P, Michel M, Godeau B. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica, 98:881-887 (IF2013=5,868) Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T. (2013) Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial. J Clin Oncol, 31:104-110 (IF 2013=17,960) 2012
Herault O, Hope KJ, Deneault E, Mayotte N, Chagraoui J, Wilhelm BT, Cellot S, Sauvageau M, Andrade-Navarro M, Hébert J, Sauvageau G. A role for GPx3 in activity of normal and leukemia stem cells. (2012) J Exp Med, 209:895-901 (IF2012=13,214) Ponte AL, Ribeiro-Fleury T, Chabot V, Gouilleux F, Langonné A, Herault O, Charbord P, Domenech J. G-CSF stimulation of bone marrow mesenchymal stromal cells promotes CD34+ cell migration via a MMP-2-dependent mechanism. (2012) Stem Cells Dev, 21:3162-3172 (IF2012=4,670) Ben Azouna N, Jenhani F, Regaya Z, Berrais L, Ben Othman T, Ducroq E, Domenech J. (2012) Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. Stem Cell Res Ther, 3:6 (IF2012=3,652) Trost M, Sauvageau
M, Herault O, Deleris P, Chagraoui J,
Mayotte N, Meloche S, Sauvageau G, Thibault P. (2012) Comparative phosphoproteome
analysis of stem cell leukemias reveals differential cytoplasmic translocation
of PRC2 polycomb proteins. Blood, 120:e17-27 (IF2012=9,060) Bire S, Rouleux-Bonnin F. (2012) Transposable elements as tools for reshaping the genome: it is a huge world after all! Methods Mol Biol, 859:1-28 (revue) Varon C, Dubus P, Mazurier F, Asencio C, Chambonnier L, Ferrand J, Giese A, Senant-Dugot N, Carlotti M, Mégraud F. (2012) Helicobacter pylori infection recruits bone marrow-derived cells that participate in gastric preneoplasia in mice. Gastroenterology, 142:281-291 (IF2012=12,821) Cholez E, Debuysscher V, Bourgeais J, Boudot C, Leprince J, Tron F, Brassart B, Regnier A, Bissac E, Pecnard E, Gouilleux F, Lassoued K, Gouilleux-Gruart V. (2012) Evidence for a protective role of the STAT5 transcription factor against oxidative stress in human leukemic pre-B cells. Leukemia 2012, 26:2390-2397 (IF2012=10,164) Willems L, Chapuis N, Puissant
A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault
O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D,
Lacombe C, Mayeux P, Bouscary D, Tamburini J. (2012) The dual mTORC1 and mTORC2
inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia,
26:1195-1202 (IF2012=10,164) Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, Della Valle V, Couronné L, Scourzic L, Chesnais V, Guerci-Bresler A, Slama B, Beyne-Rauzy O, Schmidt-Tanguy A, Stamatoullas-Bastard A, Dreyfus F, Prébet T, de Botton S, Vey N, Morgan MA, Cross NC, Preudhomme C, Birnbaum D, Bernard OA, Fontenay M; Groupe Francophone des Myélodysplasies. (2012) Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 119:3211-3218 (IF2012=9,060) Frisan E, Vandekerckhove J, de Thonel A, Pierre-Eugène C, Sternberg A, Arlet JB, Floquet C, Gyan E, Kosmider O, Dreyfus F, Gabet AS, Courtois G, Vyas P, Ribeil JA, Zermati Y, Lacombe C, Mayeux P, Solary E, Garrido C, Hermine O, Fontenay M. (2012) Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. Blood, 119:1532-1542 (IF2012=9,060) Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, Bruno A, Jouvet A, Polivka M, Adam C, Figarella-Branger D, Miquel C, Vital A, Ghesquières H, Gressin R, Delwail V, Taillandier L, Chinot O, Soubeyran P, Gyan E, Choquet S, Houillier C, Soussain C, Tanguy ML, Marie Y, Mokhtari K, Hoang-Xuan K. (2012) Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas. Clin Cancer Res 18:5203-5211 (IF2012=7,837) Ponciano A, de Muret A, Machet L, Gyan E, du Sorbier CM, Molinier-Frenkel V, Gaulard P, Ortonne N. (2012) Epidermotropic secondary cutaneous involvement by relapsed angioimmunoblastic T-cell lymphoma mimicking mycosis fungoides: a case report. J Cutan Pathol 39:1119-1124 (IF 2012=1,766) Renner C, Zinzani P, Gressin R, Klingbiel D, Dietrich PY, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Trojan A, Bouabdallah K, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N. (2012) A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica, 97:1085-1091 (IF2012=5,935) Chaussade H, Bastides F, Lissandre S, Blouin P, Bailly E, Chandenier J, Gyan E, Bernard L. (2012) Usefulness of corticosteroid therapy during chronic disseminated candidiasis: case reports and literature review. J Antimicrob Chemother, 67:1493-1495 (IF2012=5,338) 2011 Palazzoli F, Bire S, Bigot Y, Bonnin-Rouleux F. (2011) Landscape of chromatin control element patents: positioning effects in pharmaceutical bioproduction. Nat Biotechnol, 29:593-597 (IF2011=23,268) Rezvani HR, Kim AL, Rossignol R, Ali N, Daly M, Mahfouf W, Bellance N, Taïeb A, de Verneuil H, Bickers DR, Mazurier F. (2011) XPC silencing in normal human keratinocytes triggers metabolic alterations that drive the formation of squamous cell carcinomas. J Clin Invest, 12&:195-211 (IF2011=13,069) Rezvani HR, Ali N, Nissen LJ, Harfouche G, de Verneuil H, Taïeb A, Mazurier F. (2011) HIF-1α in epidermis: oxygen sensing, cutaneous angiogenesis, cancer, and non-cancer disorders. J Invest Dermatol, 131:1793-1805 (IF2011=6,314)
Dhennin-Duthille I, Nyga R, Yahiaoui S, Gouilleux-Gruart V, Regnier A, Lassoued K, Gouilleux F. (2011) The tumor suppressor hTid1 inhibits STAT5b activity via functional interaction. J Biol Chem, 286:5034-5042 (IF2011=4,773) Rezvani HR, Rossignol R, Ali N, Benard G, Tang X, Yang HS, Jouary T, de Verneuil H, Taïeb A, Kim AL, Mazurier F. (2011) XPC silencing in normal human keratinocytes triggers metabolic alterations through NOX-1 activation-mediated reactive oxygen species. Biochim Biophys Acta, 1807:609-619 (IF2011=4,843) Jenhani F, Durand V, Ben Azouna N, Thallet S, Ben Othmen T, Bejaoui M, Domenech J. (2011) Human cytokine expression profile in various conditioned media for in vitro expansion bone marrow and umbilical cord blood immunophenotyped mesenchymal stem cells. Transplant Proc, 43:639-643 (IF2011=1,005) Ivanovic Z, Duchez P, Chevaleyre J, Vlaski M, Lafarge X, Dazey B, Robert-Richard E, Mazurier F, Boiron JM. (2011) Clinical-scale cultures of cord blood CD34(+) cells to amplify committed progenitors and maintain stem cell activity. Cell Transplant, 20:1453-1463 Belmokhtar K, Bourguignon T, Worou ME, Khamis G, Bonnet P, Domenech J, Eder V. (2011) Regeneration of three layers vascular wall by using BMP2-treated MSC involving HIF-1α and Id1 expressions through JAK/STAT pathways. Stem Cell Rev, 7:847-859 (IF2011=3,739) Ben Nasr M, Reguaya Z, Berraies L, Maamar M, Ladeb S, Ben Othmen T, Mellouli F, Béjaoui M, Domenech J, Jenhani F. (2011) Association of stromal cell-derived factor-1-3'A polymorphism to higher mobilization of hematopoietic stem cells CD34+ in Tunisian population. Transplant Proc, 43:635-638 (IF2011=1,005) Monjanel H, Deconinck E, Perrodeau E, Gastinne T, Delwail V, Moreau A, François S, Berthou C, Gyan E, Milpied N, on behalf of the GOELAMS. (2011) Long-Term Follow-up of Tandem High-Dose Therapy with Autologous Stem Cell Support for Adults with High-Risk Age-Adjusted International Prognostic Index Aggressive non-Hodgkin's Lymphomas: a GOELAMS Pilot Study. Biol Blood Marrow Transplant, 17:935-940 (IF2011=3,873) Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B. (2011) Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood, 118:4338-4345 (IF2011=9,898) Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G. (2011) Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol, 29:3194-200 (IF2011=18,372) Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, Salles G; GELA and GOELAMS. (2011) Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica, 96:1128-1135 (IF2011=6,424) 2010 Rezvani HR, Mahfouf W, Ali N, Chemin C, Ged C, Kim AL, de Verneuil H, Taïeb A, Bickers DR, Mazurier F. (2010) Hypoxia-inducible factor-1alpha regulates the expression of nucleotide excision repair proteins in keratinocytes. Nucleic Acids Res, 38:797-809 (IF2010=7,836) Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D. (2010) Dual inhibition of PI3K and mTORC1/2 signalling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res, 16:5424-5435 (IF2010=7,338) Robert-Richard E, Lalanne M, Lamrissi-Garcia I, Guyonnet-Duperat V, Richard E, Pitard V, Mazurier F, Moreau-Gaudry F, Ged C, de Verneuil H. (2010) Modeling of congenital erythropoietic porphyria by RNA interference: a new tool for preclinical gene therapy evaluation. J Gene Med, 12:637-646 Friedbichler K, Kerenyi MA, Kovacic B, Li G, Hoelbl A, Yahiaoui S, Sexl V, Müllner EW, Fajmann S, Cerny-Reiterer S, Valent P, Beug H, Gouilleux F, Bunting KD, Moriggl R. (2010) Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood, 116:1548-1558 (IF2010=10,558) Dedieu S, Canron X, Rezvani HR, Bouchecareilh M, Mazurier F, Sinisi R, Zanda M, Moenner M, Bikfalvi A, North S. (2010) The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A. BMC Med, 8:19 (IF2010=5,750) Li G, Miskimen KL, Wang Z, Yan Xie X, Tse W, Gouilleux F, Moriggl R, Bunting KD. (2010) Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin. Leukemia, 4:1397-1405 (IF2010=8,966) Amara S, Domenech J, Jenhani F. (2010) Stromal cell-derived factor 1 polymorphism in patients infected with HIV and implications for AIDS progression in Tunisia. HIV AIDS, 2:203-209 Boudot C, Saidak Z, Boulanouar AK, Petit L, Gouilleux F, Massy Z, Brazier M, Mentaverri R, Kamel S. (2010) Implication of the calcium sensing receptor and the Phosphoinositide 3-kinase/Akt pathway in the extracellular calcium-mediated migration of RAW 264.7 osteoclast precursor cells. Bone, 46 :1416-1423 (IF2010=4,601) Kelaidi
C, Stamatoullas A, Beyne-Rauzy O, Raffoux E, Quesnel B, Guerci A, Dreyfus F,
Brechignac S, Berthou C, Prebet T, Hicheri Y, Hacini M, Delaunay J, Gourin MP,
Camo JM, Zerazhi H, Taksin AL, Legros L, Choufi B, Fenaux P; Groupe
Francophone des Myélodysplasies. (2010) Daily practice management of myelodysplastic
syndromes in France: data from 907 patients in a one-week cross-sectional study
by the Groupe Francophone des Myelodysplasies. Haematologica, 95:892-899
(IF2010=6,532)
2009 Baumgartner C, Cerny-Reiterer S, Sonneck K, Mayerhofer M, Gleixner KV, Fritz R, Kerenyi M, Boudot C, Gouilleux F, Kornfeld JW, Sillaber C, Moriggl R, Valent P. (2009) Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis. Subcellular Distribution and Role of the Transforming Oncoprotein KIT D816V. Am J Pathol, 175:2416-2429 (IF2009=5,673) El Hiani Y, Ahidouch A, Lehen'kyi V, Hague F, Gouilleux F, Mentaverri R, Kamel S, Lassoued K, Brûlé G, Ouadid-Ahidouch H. (2009) Extracellular signal-regulated kinases 1 and 2 and TRPC1 channels are required for calcium-sensing receptor-stimulated MCF-7 breast cancer cell proliferation. Cell Physiol Biochem, 23:335-346 (IF2009=3,563) Coipeau P, Rosset P, Langonné A, Gaillard J , Delorme B, Rico A, Domenech J, Charbord P, Sensebé S. (2009) Impaired differentiation potential of human trabecular bone mesenchymal stromal cells from elderly patients. Cytotherapy, 11:584-594 (IF2009=2,204) Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, Maisonneuve H, Delwail V, Gressin R, Quittet P, Vilque JP, Desablens B, Jaubert J, Ramée JF, Arakelyan N, Thyss A, Moluçon-Chabrot C, Delépine R, Milpied N, Colombat P, Deconinck E; Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS). (2009) High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood, 113:995-1001 (IF2009=10,555) 2008 Harir N, Boudot C, Friedbichler K, Sonneck K, Kondo R, Martin-Lannerée S, Kenner L, Kerenyi M, Yahiaoui S, Gouilleux-Gruart V, Gondry J, Bénit L, Dusanter-Fourt I, Lassoued K, Valent P, Moriggl R, Gouilleux F. (2008) Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI 3-kinase signaling cascade. Blood, 112:2463-2473 (IF2008=10,432)
Fontenay M, Gyan E. (2008) Apoptotic pathways to death in
myelodysplastic syndromes. Haematologica, 93 :1288-1292 (IF2008=5,978) Bonnet P, Awede B, Rochefort GY, Mirza A, Lermusiaux P, Domenech J, Eder V. (2008) Electrophysiological maturation of rat mesenchymal stem cells after induction of vascular smooth muscle cell differentiation in vitro. Stem Cells Dev, 17 :1131-1140 (IF2008=3,273) James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, Tulliez M, Lippert E, Mahon FX, Pasquet JM, Etienne G, Delhommeau F, Giraudier S, Vainchenker W, de Verneuil H. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood, 112:2429-2438 (IF2008=10,432) Mirza A, Hyvelin JM, Rochefort GY, Lermusiaux P, Antier D, Awede B, Bonnet P, Domenech J, Eder V. (2008) Undifferentiated mesenchymal stem cells seeded on a vascular prosthesis contribute to the restoration of a physiologic vascular wall. J Vasc Surg, 47 :1313-1321 (IF2008=3,770) Sinzelle L, Jégot G, Brillet B, Rouleux-Bonnin F, Bigot Y, Augé-Gouillou C. (2008) Factors acting on Mos1 transposition efficiency. BMC Mol Biol, 26:106 (IF2008=2,810) Kornfeld JW, Grebien F, Kerenyi MA, Friedbichler K, Kovacic B, Zankl B, Hoelbl A, Nivarti H, Beug H, Sexl V, Muller M, Kenner L, Mullner EW, Gouilleux F, Moriggl R. (2008) The different functions of Stat5 and chromatin alteration through Stat5 proteins. Front BioSci, 13:6237-6254 (IF2008=3,308) Blasco H, Silly S, Tournamille JF, Gyan E, Sénécal D, André V, Colombat P, Le Guellec C. (2008) The need for a better definition of therapeutic indications of carboxypeptidase in delayed elimination of methotrexate. Therapie, 63:19-28 (IF2008=0,445) 2007 Gallay N, Anani L, Lopez A, Colombat P, Binet C, Domenech J, Weksler BB, Malavasi F, Herault O. (2007) The role of CD31/PECAM-1 and CD38 antigens in marrow microenvironmental retention of acute myeloid leukemia cells. Cancer Res, 6:8624-8632 (IF2007=7,672) Harir N, Pecquet C, Kerenyi C, Sonneck K, Kovacic B, Nyga R, Brevet M, Dhennin I, Gouilleux-Gruart V, Beug H, Valent P, Lassoued K, Moriggl R, Gouilleux F. (2007) Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI 3-kinase in myeloid leukemias. Blood, 109:1678-1686 (IF2007=10,896) López Ponte A, Marais E, Gallay N, Langonné A, Delorme B, Herault O, Charbord P, Domenech J. (2007) The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities. Stem Cells, 25:1737-1745 (IF2007=7,531) Rezvani HR, Dedieu S, North S, Belloc F, Rossignol R, Letellier T, de Verneuil H, Taïeb A, Mazurier F. (2007) Hypoxia-inducible factor-1alpha, a key factor in the keratinocyte response to UVB exposure. J Biol Chem, 282:16413-16422 (IF2007=5,581) Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y. (2007) JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost, 5:859-861 (IF2007=5,947) Chaligné R, James C, Tonetti C, Besancenot R, Le Couédic JP, Fava F, Mazurier F, Godin I, Maloum K, Larbret F, Lécluse Y, Vainchenker W, Giraudier S. (2007) Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood, 110:3735-3743 (IF2007=10,896) Haond C, Farace F, Guillier M, Lécluse Y, Mazurier F, Vainchenker W, Turhan AG. (2007) Quantitative and qualitative in vitro analysis of the stem cell potential of hematopoietic cells purified from murine skeletal muscle. Cell Res, 17:783-791 (IF2007=4,217) Rébé C, Cathelin S, Launay S, Filomenko R, Prévotat L, L'Ollivier C, Gyan E, Micheau O, Grant S, Dubart-Kupperschmitt A, Fontenay M, Solary E. (2007) Caspase-8 prevents sustained activation of NF-kappaB in monocytes undergoing macrophagic differentiation. Blood, 109:1442-1450 (IF2007=10,896) Di Scala E, Rose S, Herault O, Argibay J, Cosnay P, Bozon V. (2007) Conformational state of human cardiac 5-HT(4(g)) receptors influences the functional effects of polyclonal anti-5-HT(4) receptor antibodies. Biochem Pharmacol, 73:964-971 (IF2007=4,001) Moreau P, Voillat L, Benboukher L, Mathiot C, Dumontet C, Robillard N, Herault O, Garnache F, Garand R, Varoqueaux N, Avet-Loiseau H, Harousseau JL, Bataille R; IFM group. (2007) Rituximab in CD20 positive multiple myeloma. Leukemia, 21:835-836 (IF2007=6,924) Petit A, Rouleux-Bonnin F, Lambelé M, Pollet N, Bigot Y. (2007) Properties of the various Botmar1 transcripts in imagoes of the bumble bee, Bombus terrestris (Hymenoptera: Apidae). Gene 390:52-66 (IF2007=2,871) Borowiec AS, Hague F, Harir N, Guérineau F, Gouilleux F, Lassoued K, Ouadid-Ahidouch H. (2007) IGF-1 activates hEAG K+ channels through a PI3 kinase-dependent signalling pathway in breast cancer cells. J Cell Physiol, 212:690-701 (IF2007=3,643) Guillard J, Decrop M, Gallay N, Espanel C, Boissier E, Herault O, Viaud-Massuard MC. (2007) Synthesis and biological evaluation of 7-azaindole derivatives, synthetic cytokinin analogues. Bioorg Med Chem Lett, 17:1934-1937 (IF2007=2,262) Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med, 357:1916-1927 (IF2007=52,589) Hunault M, Truchan-Graczyk M, Caillot D, Harousseau JL, Bologna S, Himberlin C, Guyotat D, Berthou C, Casassus P, Baranger L, Béné MC, Ifrah N, Gyan E; GOELAMS Group. (2007) Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial. Haematologica, 92:1623-1630 (IF2007=5,516) Espanel C, Kafando E, Hérault B, Petit A, Herault O, Binet C. (2007) [Iron deficiency anaemia: clinical presentation, biological diagnosis and management]. Transfus Clin Biol, 14:21-24 (IF2007=1,138) 2006 Dommange F, Cartron G, Espanel C, Gallay N, Domenech J, Benboubker L, Ohresser M, Colombat P, Binet C, Watier H, Herault O. (2006) CXCL12 polymorphism and malignant cell dissemination / tissue infiltration in acute myeloid leukemia. FASEB J, 20:1913-1915 (IF2006=6,721) Rochefort GY, Delorme B, Lopez A, Herault O, Bonnet P, Charbord P, Eder V, Domenech J. (2006) Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells, 24:2202-2208 (IF2006=7,924) Gyan E, Porteu F, Fontenay M. (2006) Reply to « hRap1B-retro: a novel human processed Rap1B gene blurs the picture ? » by Zemojtel et al. Leukemia, 20:146-147 (IF2006=6,146) Bideshi DK, Demattei MV, Rouleux-Bonnin F, Stasiak K, Tan Y, Bigot S, Bigot Y, Federici BA. (2006) Genomic sequence of Spodoptera frugiperda Ascovirus 1a, an enveloped, double-stranded DNA insect virus that manipulates apoptosis for viral reproduction. J Virol, 80:11791-11805 Fontenay M, Cathelin S, Amiot M, Gyan E, Solary E. (2006) Mitochondria in hematopoiesis and hematological diseases. Oncogene, 25:4757-4767 (IF2006=6,582) Bideshi DK, Demattei MV, Rouleux-Bonnin F, Stasiak K, Tan Y, Bigot S, Bigot Y, Federici BA. (2006) Genomic sequence of Spodoptera frugiperda Ascovirus 1a, an enveloped, double-stranded DNA insect virus that manipulates apoptosis for viral reproduction. J Virol 80:11791-11805 (IF2006=5,341) Maillard S, Gauduchon J, Marsaud V, Gouilleux F, Connault E, Opolon P, Fattal E, Sola B, Renoir JM. (2006) Improved antitumoral properties of pure antiestrogen RU 58668-loaded liposomes in multiple myeloma. J Steroid Biochem Mol Biol, 100:67-78 (IF2006=2,825) |